Altre lingue RemeGen Co., Ltd.

Azioni

9995

CNE1000048G6

Tempo differito Hong Kong S.E. Altri mercati azionari 05:17:56 25/04/2024			Variaz. 5gg	Var. 1 gen.
31,25 ^HKD	+6,29%		+14,65%	-16,42%

04/04	Remegen ottiene la designazione Fast Track della FDA statunitense per il farmaco contro la sindrome di Sjogren primaria	MT
02/04	Remegen Co., Ltd. annuncia che la FDA concede a Telitacicept la designazione Fast Track per il trattamento della pSS	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	04/04
Remegen Co., Ltd. Announces FDA Grants Telitacicept Fast Track designation for Treatment of pSS	02/04
Remegen Plans A-Share Private Placement to Fund New Drug Development Project	29/03
RemeGen Co., Ltd. announced that it expects to receive CNY 2.549999941 billion in funding	29/03
RemeGen Co., Ltd.(XSSC:688331) added to FTSE All-World Index	18/03
RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin for Cervical Cancer At ESGO 2024	11/03
RemeGen's 2023 Net Loss Widens; Revenue Jumps 40%	26/02
RemeGen Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
RemeGen's Loss to Widen in 2023	31/01
RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023	30/01
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	24/01
RemeGen Buys Back HK$12 Million Worth of Hong Kong Shares	23/01
RemeGen Denies Rumors of Tight Cash Flow, Funding Hurdles	17/01
La población china vuelve a descender, con la tasa de natalidad más baja en los registros	17/01
RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients	12/01
RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment	28/12
RemeGen Gets Full Approval for Telitacicept	22/11
RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA	22/11
RemeGen to Hike Annual Caps for Services Agreements	20/11
RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology	15/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue RemeGen Co., Ltd.

Azioni

9995

CNE1000048G6

Altre lingue

Filtri